Company intelligence / Profile preview

Metabolics Pharma, Inc.

Philadelphia, Pennsylvania, United Statesmetabolicspharma.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Metabolics Pharma has a Phase 1 clinical trial (NCT05925920) that is active but not recruiting. The trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes[1].

Therapeutic areas
Endocrinology
Modalities
Small moleculespeptides
Industry
Biotech
02

Drug pipeline

3 assets

ENT-03S

1

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Metabolics Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabolics Pharma, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call